
CLAIMS

1. A pharmaceutical composition comprising



(Conjugate **57**) or a pharmaceutically acceptable salt thereof, acetate buffer, mannitol, and solutol.

2. The pharmaceutical composition of claim 1, wherein the acetate buffer has a strength of at least 30mM.

3. The pharmaceutical composition of claim 1, wherein the acetate buffer has a strength of at least 40mM.

4. The pharmaceutical composition of claim 1, wherein the mannitol has a concentration of about 5%.

5. The pharmaceutical composition of claim 1, wherein the solutol has a concentration of about 2%.

6. Use of Conjugate **57** or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of tumor in a subject, wherein the dose of Conjugate **57** is based on the body surface area (BSA) of the subject, and wherein the dose of Conjugate **57** is 8.8 mg/m^2 or less than 8.8 mg/m^2.

7. The use of claim 6, wherein the tumor is a neuroendocrine tumor (NET).

8. The use of claim 6, wherein the tumor selected from the group consisting of

gastroenteropancreatic (GEP), gastrointestinal (GI), pancreatic, lung, prostate, and thymus neuroendocrine tumor.

9. The use of claim 6, wherein the tumor is small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung.

10. Conjugate 57 or a pharmaceutically acceptable salt thereof, for use in therapy.